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Cellular and molecular aspects of drug transport in the kidney. membrane transport proteins mediate vectorial transepi-
The kidney plays an important role in the elimination of numer- thelial transport. The kidney has developed high-capac-
ous hydrophilic xenobiotics, including drugs, toxins, and endog- ity transport systems to prevent urinary loss of filteredenous compounds. It has developed high-capacity transport
nutrients such as d-glucose, amino acids, and oligopep-systems to prevent urinary loss of filtered nutrients, as well as
tides, as well as inorganic ions, and simultaneously toelectrolytes, and simultaneously to facilitate tubular secretion
of a wide range of organic ions. Transport systems for organic facilitate tubular secretion of a variety of xenobiotics
anions and cations are primarily involved in the secretion of that escape hepatic extraction processes.
drugs in renal tubules. The identification and characterization The transport systems responsible for renal tubularof organic anion and cation transporters have been progressing
secretion of drugs have been classified as either organicat the molecular level. To date, many members of the organic
anion or cation transport systems based on their prefer-anion transporter (OAT), organic cation transporter (OCT),
and organic anion-transporting polypeptide (oatp) gene fami- ential substrate selectivity [1, 2]. The secretory transport
lies have been found to mediate the transport of diverse organic process is performed effectively by two distinct classes
anions and cations. It has also been suggested that ATP-depen-
of transporters: one localized at the basolateral mem-dent primary active transporters such as MDR1/P-glycoprotein
branes to mediate cellular uptake of substrates fromand the multidrug resistance-associated protein (MRP) gene
family function as efflux pumps of renal tubular cells for more blood and the other at the brush-border membranes to
hydrophobic molecules and anionic conjugates. Tubular reab- mediate exit of cellular substrates into the tubular lumen
sorption of peptide-like drugs such as b-lactam antibiotics across [3–5]. Over the last several years, considerable progress
the brush-border membranes appears to be mediated by two
has been made regarding the identification and charac-distinct H1/peptide cotransporters: PEPT1 and PEPT2. Renal
terization of organic anion and cation transporters at thedisposition of drugs is the consequence of interaction and/or
transport via these diverse secretory and absorptive transport- molecular level [6–9]. In addition to these organic ion
ers in renal tubules. Studies of the functional characteristics, transporters, the adenosine 59-triphosphate (ATP)-depen-
such as substrate specificity and transport mechanisms, and dent primary active transporters such as P-glycoprotein
of the localization of cloned drug transporters could provide
[10, 11] and the multidrug resistance-associated proteininformation regarding the cellular network involved in renal
(MRP) family have been suggested to function as thehandling of drugs. Detailed information concerning molecular
and cellular aspects of drug transporters expressed in the kid- drug efflux pumps in renal tubules [12, 13].
ney has facilitated studies of the mechanisms underlying renal Renal reabsorption of some classes of drugs is medi-
disposition as well as transporter-mediated drug interactions. ated by nutrient transporters in proximal tubules. Several
peptide-like drugs such as oral b-lactam antibiotics are
known to undergo both secretion and reabsorption in
The kidney, as well as the liver, plays a pivotal role renal tubules [14]. Organic anion and cation transporters
in the elimination of numerous potentially toxic xenobi- have been suggested to mediate the secretory transport
otics, including drugs, toxins, and endogenous metabo- of these antibiotics. The reabsorption of most peptide-
lites. Renal elimination of drugs involves glomerular fil- like drugs from the glomerular filtrate is mediated by
tration, tubular secretion, and tubular reabsorption. Of oligopeptide transporters localized at the brush-border
these, the secretion and reabsorption of drugs in renal membranes of proximal tubular cells, influencing their
tubules are essentially saturable processes, as plasma pharmacokinetic profiles and therapeutic efficacy [14].
Therefore, renal handling of most charged drugs is the
result of the interaction and transport processes throughKey words: renal tubules, organic anion transporter, cation transporter,
P-glycoprotein, MRP, drug interaction. secretory organic ion transporters and, in certain cases,
through the reabsorptive nutrient transporters in renalReceived for publication December 29, 1999
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sorption of drugs. Such information would be of clinical
importance for predicting interactions between drugs
and/or their metabolites with renal transporters, which
may result in competition at a tubular secretion or reab-
sorption site and be accompanied by significant adverse
effects.
This review deals with the recent advances in cellular
and molecular studies regarding identification and com-
parative characterization of renal drug transporters. An
insight into their pharmacological and toxicological char-
acteristics is also given, as well as a brief historical back-
ground.
FUNCTIONAL CHARACTERISTICS OF
ORGANIC ANION TRANSPORT SYSTEMS
Fig. 1. Mechanisms of organic anion transport in renal tubular cells.More than 60 years ago, Smith, Goldring, and Chassis
Cellular uptake of organic anions across basolateral membranes (BLM)
reported that the anionic dye phenol red was eliminated is mediated by OAT1 (1), which is an organic anion/dicarboxylate
exchanger, and by OAT2 (2) and OAT3 (3). Anionic drug conjugatesfrom renal plasma in a single pass through the kidney
with glutathione may be extruded from cells into blood by MRP1 (4).[15]. Since then, the renal organic anion transport system
Exit of cellular organic anions across brush-border membranes (BBM)
has been extensively studied, and this secretory system is mediated by unidentified transmembrane potential-dependent or-
ganic anion transporter (5) and organic anion/anion (X2) exchangerappears to mediate renal excretion of a wide range of
(6). Bidirectional transport of hydrophobic anions such as methotrexatesmall foreign compounds, including drugs, their metabo-
and folic acid in the brush-border membranes is mediated by OAT-K1
lites, and diverse xenobiotics. Thus, the organic anion (7). OAT-K2 (8) may also participate in tubular reabsorption and/or
secretion of hydrophobic anions such as bile acids, methotrexate, andtransport system plays a critical role in protecting against
prostaglandin E2. MRP2/cMOAT (9) may contribute to tubular secre-the potential toxic effects of anionic compounds by medi- tion of anionic conjugates of hydrophobic compounds.
ating their excretion into urine.
The secretion of organic anions in the renal tubules
is mediated by the concerted function of two distinct
transport steps at the peritubular basolateral membranes PAH/Cl2 exchange, and the PAH/PAH exchange was
and luminal brush-border membranes of the tubular cells insensitive to the membrane potential. The potential-
(Fig. 1) [3–7]. The energy-dependent uphill uptake is stimulated PAH uptake was more sensitive to anionic
required for the basolateral entry step of the negatively drugs such as furosemide and 4,49-diisothiocyano-2,29-
charged anions, as they must be translocated against an disulfonic stilbene than PAH/PAH exchange [20]. These
electrical potential barrier across the basolateral mem- findings suggest that PAH is transported by two distinct
branes. Shimada, Moewes, and Burckhardt reported that transport systems in rat renal brush-border membranes,
uptake of para-aminohippurate (PAH), a marker sub- that is, a potential-sensitive transport system (Fig. 1, #5)
strate for the renal organic anion transport system in the and an anion exchanger (Fig. 1, #6). The anion exchanger
isolated basolateral membrane vesicles, was markedly is found to be expressed in urate-reabsorbing species
enhanced in the presence of an outward a-ketoglutarate such as the rat and the dog, and accepts various organic
gradient [16]. This finding suggested that dicarboxylates and inorganic anions (including PAH, urate, Cl2, Br2,
are the physiological counterions for the uphill transport HCO32, and OH2) as substrates [21, 22]. In addition to
of organic anions. The outward a-ketoglutarate gradient these proposed organic anion transport systems, func-
is sustained not only by intracellular metabolic dicarbox- tional studies using isolated perfused renal tubules have
ylate generation, but also by the Na1/a-ketoglutarate demonstrated the participation of multiple transport
cotransport system driven by the inward Na1 gradient proteins in secretion of organic anions at the brush bor-
[17], which is established by Na1,K1-ATPase. Therefore, der membranes (discussed later in this article) [7].
the basolateral transport of organic anions appears to
be driven by indirect coupling to the Na1 gradient
IDENTIFICATION OF ORGANIC
through Na1/a-ketoglutarate cotransport and organic
ANION TRANSPORTERS
anion/dicarboxylate exchange (Fig. 1, #1) [18].
Oat familyIn rat renal brush-border membrane vesicles, the up-
take of PAH was stimulated by an inside-positive mem- As the first step toward the molecular characterization
of organic anion transport (OAT) proteins through ex-brane potential created by K1 and valinomycin [19]. In
addition, PAH uptake was stimulated by PAH/PAH or pression cloning, the functional expression of both fum-
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arate- and lithium-sensitive glutarate and probenecid- tubules [37]. In addition, efflux of intracellular a-ketoglu-
sensitive PAH transporter were investigated in Xenopus tarate from the OK cells to the basolateral side medium
oocytes injected with rat kidney poly(A)1 RNA [23]. was stimulated in the presence of PAH, suggesting that
Expression of size-fractionated mRNA indicated that the PAH/dicarboxylate exchange system functions in this
the active species, with respect to PAH transport activi- cell line [38]. Partial sequence analysis by reverse tran-
ties, was in the range of 1.8 to 3.5 kb. In 1997, Sekine et scription-polymerase chain reaction (RT-PCR) suggested
al [24] and Sweet, Wolff, and Pritchard [25] successfully that the opossum homologue of OAT1 was expressed
isolated a 2.2 kb cDNA clone from rat kidney encoding in OK cells (unpublished data). PAH uptake across the
the PAH/dicarboxylate exchanger protein by expression basolateral membranes of OK cell monolayers grown on
cloning with oocytes. This was designated as OAT1. Rat microporous membrane filters was markedly inhibited
(r) OAT1 is comprised of 551 amino acid proteins with by a phorbol esters such as phorbol 12-myristate 13-
12 putative membrane-spanning domains. Wolff et al acetate, suggesting that the PAH transport system in OK
also isolated the cDNA clone from winter flounder cod- cells could be under the regulatory control of protein
ing for the PAH/dicarboxylate exchange, designated as kinase C [39]. Parathyroid hormone was found to inhibit
fOAT1, which was 2.8 kb in length and encoded a protein PAH uptake by OK cells through protein kinase C acti-
of 562 amino acids [26]. When expressed in oocytes, vation and was assumed to be involved in the regulation
both rat and flounder OAT1 mediated Na1-independent of the organic anion transporter [39]. Similar inhibitory
PAH uptake with apparent Km values ranging from 14.3 regulation by protein kinase C as well as substrate speci-
to 70 mmol/L [24–26]. The uptake rate of PAH was ficity has been demonstrated for rOAT1 expressed in
markedly enhanced in the presence of an outward gradi- oocytes [28]. The physiological implications for this regu-
ent of dicarboxylate, indicating that OAT1 functions as lation of OAT1 remain to be elucidated.
an organic anion/dicarboxylate exchanger [24–26]. rOAT1 Other members with significant homology to OAT1
had a wide substrate specificity for endogenous anions have been identified (Table 1).
such as cyclic nucleotides, prostaglandins, uric acid, and Novel liver-specific transport protein (NLT), isolated
structurally diverse drugs such as b-lactam antibiotics, as a liver-specific transporter from the rat [40], shows a
methotrexate, and nonsteroidal anti-inflammatory drugs 42% identity with rOAT1. When expressed in oocytes,
(NSAIDs) [27, 28]. In addition, it was reported that NLT mediated the uptake of organic anions such as
rOAT1 mediated transport of ochratoxin A, a potent salicylate, acetylsalicylate, prostaglandin E2, dicarboxy-nephrotoxin, suggesting that accumulation of the toxin lates, and PAH [41]. Expression of NLT mRNA was
via rOAT1 in proximal tubules may be the primary event predominantly detected in the liver and to a lesser extent
in the development of ochratoxin A-induced nephrotox-
in the kidney [40, 41]. Thus, it has been postulated that
icity [29]. Immunohistochemical analysis suggested that
rat NLT should be renamed rOAT2. In contrast torOAT1 is exclusively expressed in the S2 segments of
OAT1, NLT/rOAT2 appears not to be an organic anion/proximal tubules in the kidney and is localized to the
dicarboxylate exchanger, and its driving force has notbasolateral membranes of these segments [30].
been identified (Fig. 1, #2).Two cDNAs, hOAT1-1 encoding 556 amino acid pro-
A cDNA encoding another member of the multispe-teins [31] and hOAT1-2 (PAHT, hROAT1) encoding
cific organic anion transporter family, rOAT3, was iso-550 amino acid proteins [31–34] were identified in the
lated from rat brain by the RT-PCR cloning methodhuman kidney. hOAT1-1 as well as rOAT1 appeared to
based on the sequence conserved among rOAT1, rOAT2be the PAH/dicarboxylate exchanger localized to the
and rat organic cation transporter (rOCT1; Fig. 1, #3)basolateral membranes of proximal tubule and multispe-
[42]. rOAT3 shows 49, 39, and 36% identity with rOAT1,cific for various xenobiotics and endogenous substances
rOAT2, and rOCT1, respectively. rOAT3 mRNA ap-[31]. In contrast, PAHT was suggested to show a narrow
peared to be expressed in the liver, brain, kidney, andsubstrate specificity, since prostaglandins and methotrex-
eye [42]. When expressed in oocytes, rOAT3 mediatedate were not transported [33]. There may be differences
the uptake of organic anions such as PAH (Km valuein substrate specificity between the two hOAT1 isoforms,
of 65 mmol/L), ochratoxin A (Km value of 0.74 mmol/L),which could be derived by the alternative-splicing mech-
and estrone sulfate (Km value of 2.3 mmol/L), and theanisms.
cationic drug cimetidine. rOAT3-mediated uptake of es-It has been demonstrated that a cultured renal epithe-
trone sulfate was inhibited by other anions such as sulfo-lial cell line derived from opossum kidney (OK) pos-
bromophthalein (BSP), probenecid, indocyanine green,sesses transcellular transport activity for PAH, corre-
bumetanide, piroxicam, furosemide, azidodeoxythymi-sponding to renal tubular secretion [35, 36]. Studies using
dine, and benzylpenicillin, but not by cationic com-various organic anions showed that the PAH transport
pounds such as tetraethylammonium (TEA), guanidine,system in the basolateral membranes of OK cells has
a similar substrate specificity to that in renal proximal or quinidine [42]. rOAT3 has been suggested to partici-
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Table 1. Organic ion transporter family
Transporter Species Accession Chromosome Tissue distribution Substratesa
OAT1 Human (SLC22A6) AB009697 11q11-q13.1 Kidney..brain (rat) PAH, a-KG, cAMP,
Rat AB004559 cGMP, NSAIDs,
Mouse (NKT) U52842 methotrexate, b-lactam
Winter flounder Z97028 antibiotics, ochratoxin A,
uric acid, prostaglandin E2
OAT2 Human (SLC22A7, NLT) AF097518 Liver..kidney (rat) PAH, a-KG, salicylate,
Rat (NLT) L27651 acetylsalicylate,
prostaglandin E2
OAT3 Human (SLC22A8) AF097491 11q11-q12 Liver.kidney.brain PAH, ochratoxin A,
Rat AB017466 (rat) estrone-3-sulfate,
cimetidine
OCTN1 Human (SCL22A4) AB007448 5 Kidney, spleen, bone l-carnitine, quinidine,
Rat AF169831 marrow, etc. verapamil, TEA
Mouse AF111425 ubiquitous (human)
OCTN2 Human (SLC22A5) AF057164 5q31 Kidney, skeletal muscle, l-carnitine, TEA
Rat (CT1, UST1) AB017260 placenta, pancreas
Mouse AF110417 (human)
OCT1 Human (SLC22A1) U77086 6q26 Liver, kidney.small TEA, NMN, choline,
Rabbit AF015958 intestine (rat) dopamine, MPP
Rat X78855
Mouse AF010259
OCT1A Rat U76379 TEA
OCT2 Human (SLC22A2) X98333 6q26 Kidney..brain (rat) TEA, choline dopamine,
Pig Y09400 MPP, guanidine
Rat D83044
Mouse AJ006036
OCT3 Human (SLC22A3) AF078749 6q26-q27 Placenta..small TEA, guanidine
Rat AF055286 intestine, heart,
Mouse AF078750 brain.kidney,
lung (rat)
RST Mouse AB05451 Kidney
UST2 Rat AJ001933 Ubiquitous
a The substrate specificities were examined for each rat clone
pate in the excretion and/or detoxification of endogenous the kidney. In the HeLa/vaccinia transient expression
system, oatp did not mediate transport of PAH, urate,and exogenous organic anions, especially from the brain.
sulfate, or eicosanoids [45]. The oatp1-mediated uptake
Organic anion-transporting polypeptide family of BSP was inhibited by corticosterone sulfate, spirono-
lactone, and several other steroids, which could representIn 1994, Jacquemin et al isolated a cDNA clone from
rat liver coding for the organic anion-transporting poly- high-affinity endogenous oatp1 substrates. Estradiol 17b-
D-glucuronide appeared to be one of the preferred sub-peptide (oatp1) by expression cloning [43]. The clone
encodes 670 amino acids with 10 putative transmem- strates of oatp1, suggesting that the transporter may
serve as an apical exit pathway for steroids followingbrane domains. The oatp1-mediated Na1-independent
uptake of BSP which was Cl2 dependent in the presence the conjugated steroids with a strong 17- or 3-position
anionic group in tubules [45].of bovine serum albumin [43]. In addition to BSP, oatp1
also mediated Na1-independent uptake of conjugated Two cDNAs encoding other members of the oatp gene
family, oatp2 [46] and oatp3 [47], were isolated fromand unconjugated bile acids. Northern blot analysis dem-
onstrated expression of oatp1 mRNA in rat liver, kidney, the rat brain and retina, respectively (Table 2). Oocytes
injected with synthetic RNA encoding oatp2 and oatp3brain, lung, skeletal muscle, and proximal colon. Immu-
nohistochemical examination of the liver revealed the showed an uptake of taurocholate, thyroxin, and triiodo-
thyronine in a saturable manner. In addition, the oatp2-sinusoidal plasma membrane localization of oatp1 [44].
In rat kidney, oatp1 was detected in renal brush-border expressing oocytes stimulated the uptake of cardiac gly-
cosides such as digoxin and ouabain. The oatp2 mRNAmembranes in the S3 segment of the proximal tubule
of the outer medulla [44]. Differential processing and was found to be widely expressed in central nervous
system neuroneal cells as well as in the retina and liver.trafficking of oatp1 in the liver and kidney have been
suggested. As oatp1 mRNA is strongly expressed in the In contrast, oatp3 mRNA was expressed in the kidney
and moderately expressed in the retina. It has been sug-kidney, it has been suggested that the transporter partici-
pates in the secretion of a variety of organic anions by gested that oatp2 and oatp3 are multifunctional trans-
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Table 2. Organic anion transporting polypeptide family
Transporter Species Accession Chromosome Tissue distribution Substratesa
oatp1 Rat L19031 Liver.kidney BSP, ouabain, taurocholic acid, cholic
acid, 17b-estradiol glucuronide,
leukotriene C4, DNP-SG
oatp2 Rat U88036 Liver.brain.retina Digoxin, ouabain, taurocholic acid,
cholic acid, 17b-estradiol glucuronide,
thyroxine, 3,5,39-triiodo-l-thyronine
oatp3 Rat AF041105 Kidney.retina, liver Taurocholic acid, thyroxine,
3,5,39-triiodo-l-thyronine
OATP Human U21943 12 Brain BSP, taurocholic acid, cholic acid,
(SLC21A3) glycocholic acid, taurochenodeoxy-
cholic acid, tauroursodeoxycholic acid
OAT-K1 Rat D79981 Kidney Methotrexate, folic acid
OAT-K2 Rat AB012662 Kidney Methotrexate, folic acid, taurocholic
acid, prostaglandin E2
PGT Human U70867 3q21 Ubiquitous (human) Prostanoids
Rat (matrin F/G) M64862
a The substrate specificities were examined for each rat clone except OATP
porters in the brain, retina, liver, and kidney. The mem- transport of methotrexate in a competitive manner [51].
Other NSAIDs, including ibuprofen, flufenamate andbrane localization of both transporters has not yet been
identified. phenylbutazone, but not salicylate, showed potent inhib-
itory effects on the OAT-K1–mediated uptake of metho-In 1996, a cDNA encoding a member of the oatp
gene family, designated as OAT-K1, was isolated in our trexate. These findings suggested that OAT-K1 could
be one of the sites of interaction for methotrexate andlaboratory (Table 2) [48]. Rat OAT-K1 is comprised of
669 amino acids and shows 72% identity with rat oatp1. NSAIDs in the kidney.
Another kidney-specific isoform of the oatp family,Northern hybridization indicated that OAT-K1 mRNA
of 2.8 kb was expressed exclusively in rat kidney. In designated as OAT-K2 [52], was isolated from rat kid-
ney. OAT-K2 is comprised of 498 amino acids and showsLLC-PK1 cells stably transfected with OAT-K1 cDNA,
the transporter protein was localized in the basolateral 91% identity with rat OAT-K1. OAT-K2 mRNA was
detected in proximal convoluted and straight tubules andmembranes and mediated Na1-independent uptake of
methotrexate (Km value of 1 mmol/L), folate, but not cortical collecting ducts. In contrast to OAT-K1, OAT-
K2 mediated the uptake of various hydrophobic anionsof PAH, taurocholate, prostaglandin E2, or leukotriene
C4 [48]. By RT-PCR detection, OAT-K1 mRNA was such as taurocholate, methotrexate, folate, and prosta-
glandin E2. When transfected into MDCK cells, OAT-found predominantly in superficial and juxtamedullary
proximal straight tubules [49]. Western blotting with K2 was localized functionally to the apical membranes
and transported taurocholate with a Km value of 10antirat OAT-K1 antibodies revealed that a transporter
protein with an apparent molecular mass of 40 kD (cal- mmol/L. Several organic anions, bile acids, cardiac glyco-
sides, and steroids showed potent inhibitory effects onculated molecular mass of 74 kD) was expressed exclu-
sively in rat kidney brush-border membranes (Fig. 1, #7) OAT-K2–mediated uptake of taurocholate. OAT-K2
may participate in reabsorption and/or secretion of hy-[49]. When transfected into Madin-Darby canine kidney
(MDCK) cells, OAT-K1 mediated bidirectional trans- drophobic anions in the kidney (Fig. 1, #7).
port of methotrexate at the apical membranes, but not
Multidrug resistance-associated protein familyat the basolateral membranes [50]. The protein with an
apparent molecular mass of 50 kD was detected in the MRP1, identified from a human multidrug-resistant
lung cancer cell line as a glutathione S-conjugate (GS-X)plasma membrane fractions of MDCK cells transfected
with OAT-K1 by Western blotting. In contrast, OAT- pump [53] able to transport anionic drug conjugates as
well as unmodified anticancer drugs out of the cell, alsoK1 protein of about 70 kD was found in the basolateral
membranes of the transfected LLC-PK1 cells [49]. There- plays a role in detoxification in tissues including the liver,
lung, and kidney (Fig. 1, #4) [54, 55]. MRP1 is an integralfore, we suggested that the proteolytic processing and/or
excision of OAT-K1 found in renal tubular cells would membrane glycoprotein, belonging to the ATP-binding
cassette (ABC) transporter superfamily [54]. The mostbe retained in MDCK cells, but not in LLC-PK1 cells.
Moreover, we found that the mechanisms of the mem- extensively studied member of the MRP family is MRP2/
cMOAT, the canalicular multispecific organic anionbrane sorting of OAT-K1 are different between MDCK
and LLC-PK1 cells. In the OAT-K1-transfected cells, transporter, which was found to be defective in mutant
rats, such as Eisai hyperbilirubinemic (EHBR) [56, 57]NSAIDs such as indomethacin and ketoprofen inhibited
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Table 3. ABC transporter family
Transporter Species Accession Chromosome Tissue distribution Substratesa
Pgp Human (MDR1, ABCB1) M14758 7q21 Liver, small intestine, Hydrophobic (cationic)
Rat (mdr1b) L15079 kidney, brain, adrenal compounds, anticancer
Mouse (mdr1a) M33581 gland (human) agents, digoxin, immuno-
Mouse (mdr1b) J03398 suppressants, steroids
MRP1 Humans (GS-X, ABCC1) L05628 16p13.1 Liver, brain, kidney Anticancer agents, anionic
Mouse AF022908 (human) conjugates with glutathione,
sulfate or glucuronide
MRP2 Human (cMOAT, ABCC2) U49248 10q24 Liver, kidney (rat) Organic anions, anionic
Rat (cMOAT) AB017446 conjugates with glutathione,
sulfate or glucuronide,
bilirubin glucuronide
MRP3 Human (cMOAT2, ABCC3) AB010887 17q21.3 Liver, small intestine Anionic conjugates
Rat (MLP2) AB010467 (human)
MRP6 Human (ABCC6) AF07662 16p13.1
Rat (MLP1) U73038
Mouse AB028737
a The substrate specificities were examined for each human clone
and TR2 [58] rats. MRP2/cMOAT shares 49% amino FUNCTIONAL CHARACTERISTICS OF
acid identity with MRP1. The absence of MRP2/cMOAT ORGANIC CATION TRANSPORT SYSTEMS
in humans results in the Dubin–Johnson syndrome [59]. In the kidney, organic cation transport systems play
Most substrates for MRP1 and MRP2/cMOAT are an- physiological and pharmacological roles in the reabsorp-
ionic conjugates of hydrophobic substances such as the tion and/or excretion of endogenous organic cations such
glutathione S-conjugate leukotriene C4 and the glucuro- as guanidine, choline, N1-methylnicotinamide (NMN),
nide conjugate of bilirubin. The Km value (1.0 mmol/L) bioactive monoamines (dopamine, epinephrine, and his-
of human MRP2/cMOAT for leukotriene C4 was tenfold tamine), cationic drugs (TEA, cimetidine, procainamide,
higher than that of MRP1 (0.1 mmol/L) [54]. There are and quinidine), and cationic toxins. In this way, the ho-
kinetic differences between the two MRP isoforms, but meostasis of these diverse cations is maintained. Organic
no substrates or inhibitors that are selective for either cation transport activity has been found primarily in re-
MRP1 or MRP2/cMOAT have yet been found. MRP2/ nal proximal tubules, but has also been detected in distal
cMOAT was identified in the brush border membranes tubules and collecting ducts [63–65]. Functional mea-
of segments S1, S2, and S3 of rat kidney proximal tubules surements of organic cation transport system were exam-
by immunohistochemical analysis [12]. MRP2/cMOAT ined employing isolated renal tubules [66–68], stop-flow
in the kidney has been suggested to contribute to cellular
microperfusion of proximal tubule [69], and plasma
detoxification and to the secretion of endogenous and
membrane vesicles isolated from renal proximal tubulesxenobiotic anionic compounds, most of which are conju-
[70–83]. These studies suggested that secretion of cat-gates, from the blood into urine (Fig. 1, #9).
ionic substances in renal tubules is operated effectivelyOther members of the MRP gene family, MRP3 and
by the cooperative function of two distinct organic cationMRP6, were found to be expressed in the kidney (Table
transporters: one facilitated by the transmembrane elec-3). MRP3 was found in human liver, colon, pancreas,
trical potential difference in the basolateral membranesbut was less abundant in the kidney [60]. MRP3 was
and the other driven by the transmembrane H1 gradientsuggested to be the basolateral MRP isoform, which
in the brush border membranes (Fig. 2, #4). LLC-PK1mediates the cellular extrusion of glucuronide conju-
cells derived from porcine kidney have been demon-gates, and to be up-regulated when the canalicular secre-
strated to mediate unidirectional transcellular transporttion of anionic conjugates by MRP2/cMOAT in the liver
of TEA from the basolateral medium to the apical me-is impaired [61]. In MDCK cells transfected with MRP3
dium, corresponding to renal tubular secretion [84]. WecDNA, MRP3 was localized to the basolateral mem-
found that LLC-PK1 cells are useful for studying mecha-branes and mediated efflux of the organic anion S-(2,4-
nisms of cationic xenobiotics and drug interactions medi-dinitrophenyl-)glutathione into the basolateral side of
ated by organic cation transporters in vitro [85–87].the monolayer [62]. The most recently discovered mem-
In 1979, Kinsella et al reported initial studies of NMNber of the family, MRP6, was found to be highly ex-
uptake by the basolateral and brush-border membranepressed in the liver and kidney and weakly expressed in
vesicles from dog kidney, suggesting the existence ofa few other tissues [13]. The intrarenal distribution, mem-
distinct transport systems at each membrane [76]. Webrane localization, and substrate selectivity of MRP6
have not been elucidated. reported that the valinomycin- and K1-induced trans-
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such transport systems could exist, as renal secretion of
type 2 cations such as quinine and quinidine has been
observed [90]. Therefore, the multispecific organic cation
transport systems in renal basolateral membranes may
comprise more than a single transporter protein. Consis-
tent with these functional studies, some organic cation
transporters have been identified at the molecular level
(discussed later in this article).
Functional properties of the organic cation transport
system in renal brush-border membranes have been ex-
tensively investigated using isolated brush-border mem-
brane vesicles [70–73, 76–83] and cultured renal epithe-
lial cell lines [84–87]. A large body of data from these
studies revealed that the transport system in these mem-
branes is mediated by an electroneutral H1/organic cat-
ion antiporter energized by transmembrane H1 gradient,Fig. 2. Mechanisms of organic cation transport in renal tubular cells.
Cellular uptake of organic cations across the basolateral membranes which can be sustained by the Na1/H1 exchanger and/or
(BLM) is mediated primarily by membrane potential-dependent or-
H1-ATPase (Fig. 2). The H1 and organic cation are tightlyganic cation transporters such as OCT1 (1) and OCT2 (2). OCT3 (3)
coupled as transient uphill uptake (overshoot phenome-may contribute in part to the cellular uptake of organic cations. Exit
of cellular organic cations across brush-border membranes (BBM) is non) of substrates such as TEA, and cimetidine was ob-
mediated principally by unidentified H1/organic cation antiporter (4).
served in the presence of an initial outward H1 gradientP-glycoprotein (5) is involved in tubular secretion of hydrophobic drugs
(internal vesicle pH of 6.0 and external pH of 7.5), whichsuch as digoxin, anticancer agents, and some immunosuppressants
(cyclosporine and tacrolimus). was unaffected by the valinomycin- and K1-induced
transmembrane potential difference [70]. A stoichiome-
try of 1:1 was determined for H1/organic cation exchange
[70, 77]. The existence of an additional H1/organic cationmembrane potential (inside negative) enhanced TEA
antiporter, which is more specific for guanidine, was dem-uptake by isolated renal basolateral membrane vesicles,
onstrated in the renal brush-border membranes of thebut not by brush-border membrane vesicles [70]. In rab-
rabbit [78]. This H1/guanidine antiport activity was notbit renal basolateral membranes, both transmembrane
inhibited by TEA and NMN. Trans-stimulation (cation/
potential-dependent uptake and organic cation exchange
cation exchange activity) experiments and uptake studies
were found, but these two different modes of uptake
showed that the H1/organic cation antiporter mediates
appeared to be mediated by a single transport system the translocation of a wide range of cationic compounds
rather than by two distinct systems [74, 75]. Smith, Pritch- with diverse structures, such as endogenous cations in-
ard, and Miller measured basolateral membrane poten- cluding NMN and choline, and drugs including TEA,
tial and TEA uptake using flounder and killifish renal cimetidine, procainamide, neurotoxin 1-methyl-4-phe-
tubules, and found that depolarization of the basolateral nylpyridinium (MPP), and amino-b-lactam antibiotics
membranes created by high K1 or Ba21 suppressed TEA [79–81, 83]. Therefore, the brush-border membrane H1/
uptake, and inversely that hyperpolarization stimulated organic cation antiporter appears to be a multispecific
TEA uptake [68]. Furthermore, the addition of TEA transporter for type 1 organic cations as well as the baso-
to the medium reversibly depolarized the basolateral lateral transporter. The brush-border H1/organic cation
membranes. These findings support the electrogenic fa- antiporter shows substrate specificity that is similar, but
cilitated transport of organic cations in renal basolateral not identical, to the basolateral membrane organic cation
membranes (Fig. 2). transporter [79]. Large and more hydrophobic com-
Studies using isolated rat hepatocytes have suggested pounds belonging to the type 2 cations are not translo-
the existence of two different transport systems for or- cated by the H1/organic cation antiporter. Transport
ganic cations: a type 1 system mediating uptake of small activity for such hydrophobic drugs and cations of the
hydrophilic organic cations such as TEA, cimetidine, renal brush-border membranes appears to be relatively
procainamide and guanidine, and a type 2 system mediat- small, and MDR1/P-glycoprotein (Fig. 2, #5) and/or
ing uptake of hydrophobic organic cations such as quini- other transport mechanisms could be involved in the
dine, quinine, d-tubocurarine, vecuronium, and cardiac efflux of such compounds.
glycosides [88, 89]. Most substrates of the type 2 system Several endogenous organic cations, such as mono-
have potent inhibitory effects on the type 1 system. Al- amine neurotransmitters and choline, undergo renal
though the uptake of type 2 substrates has not been tubular reabsorption as well as secretion, thereby main-
taining their homeostasis [63, 91]. As bioactive mono-directly demonstrated in renal basolateral membranes,
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amines such as dopamine and epinephrine have been ble 1). Using hybridization techniques, we isolated a
cDNA encoding OCT2 from rat kidney [97]. rOCT2 issuggested to participate in the reabsorption of Na1 along
lower nephron segments through an interaction with spe- comprised of 593 amino acids with 12 proposed putative
transmembrane domains showing a 67% identity tocific receptors, tubular uptake and efflux of monoamines
may indirectly affect renal fluid balance. For some cat- rOCT1. On Northern hybridization and RT-PCR analy-
sis, the rOCT2 mRNA transcript was detected predomi-ionic compounds and xenobiotics, this reabsorption
mechanism in the brush border membranes could be nantly in the kidney, at higher levels in the medulla than
the cortex, but not in the liver, lung, or intestine. Whenresponsible for nephrotoxicity.
rOCT2 was expressed in oocytes, uptake of TEA was
suppressed by the replacement of Na1 with K1, sug-
IDENTIFICATION OF ORGANIC
gesting that the uptake was membrane potential-depen-
CATION TRANSPORTERS
dent [97]. Acidification of extracellular medium resulted
OCT family in a decreased uptake of TEA, whereas the efflux of
TEA out of rOCT1- and rOCT2-expressing oocytes wasIn 1994, Gru¨ndemann et al identified the first member
of the organic cation transporter family, designated as not stimulated by the inward H1 gradient [98]. To com-
pare the functional characteristics of rOCT1 and rOCT2,OCT1, from the rat kidney by expression cloning [92].
Rat (r)OCT1 is comprised of 556 amino acids with 12 we established stable transfectants using MDCK cells
[99]. TEA uptake by both rOCT1 and rOCT2 transfec-putative transmembrane domains. Northern blot analy-
sis showed that rOCT1 mRNA was expressed in the tants grown on microporous membrane filters was mark-
edly enhanced when TEA was added to the basolateralliver, kidney, and intestine. In the kidney, rOCT1 mRNA
was detected in proximal tubules, glomeruli, and cortical bath medium, but not to the apical medium. TEA uptake
by both transfectants was decreased by acidifying thecollecting ducts, but not in distal tubules. By immunohis-
tochemical analysis, rOCT1 was localized to the basolat- medium pH, suggesting that rOCT1- and rOCT2-medi-
ated TEA transport were pH sensitive. Efflux of TEAeral membranes of S1 and S2 segments of proximal renal
tubules (Fig. 2, #1) and the small intestine and liver [9]. out of the transfectants was unaffected or moderately
inhibited by acidification of the medium. StructurallyWhen expressed in oocytes, rOCT1 stimulated uptake
of TEA, which was inhibited by diverse organic cations diverse organic cations, including the type 1 cations such
as MPP, cimetidine, NMN, nicotine, and procainamide,[92]. Electrophysiological experiments using rOCT1-
expressing oocytes under voltage-clamped conditions and type 2 cations, such as quinine and quinidine, inhib-
ited TEA uptake in the transfectants [99]. Inhibitiondemonstrated that positive inward currents were induced
when TEA, NMN, choline, dopamine, or MPP were experiments suggested that rOCT1 and rOCT2 had simi-
lar inhibitor binding affinities for many compounds, butadded to the bath medium, indicating that rOCT1-medi-
ated cation uptake is electrogenic [93]. showed moderate differences in inhibitor sensitivity for
several compounds such as MPP, procainamide, dopa-Human (h) OCT1 is comprised of 554 amino acids
and shows 78% identity with rOCT1. Its mRNA tran- mine, and testosterone by a factor of 2 to 3 (unpublished
data) [98, 99]. rOCT2 and hOCT2, which share 80%script was detected exclusively in the liver [94]. There
are distinct species differences in tissue distribution and amino acid identity, have been shown to accept mono-
amine neurotransmitters such as dopamine, norepineph-histochemical localization of OCT1. After expression in
oocytes, hOCT1 mediated the uptake of type 1 organic rine, epinephrine, 5-hydroxytryptamine, and amantadine
as substrates [100, 101]. These findings raise the possibil-cations such as NMN, TEA, and MPP, suggesting that
hOCT1 may primarily participate in hepatic excretion of ity that OCT2 plays a physiological role in renal handling
of some bioactive monoamines and implies that theorganic cations in humans [95]. hOCT1-mediated MPP
uptake was saturable with a Km value of 14.6 mmol/L transporter is indirectly involved in the physiological
function of these monoamines such as renal tubular reab-and was sensitive to transmembrane potential. The type
2 hydrophobic cations such as vecuronium and decyn- sorption of Na1.
Recently, we reported that slices and isolated basolat-ium-22 as well as the type 1 hydrophilic cations such as
TEA and NMN inhibited MPP uptake. hOCT1 has lower eral membrane vesicles of male rat kidney showed a
higher transport activity for TEA than those of femalebinding affinity for several cations such as decynium-22,
tetrapentylammonium, quinine, and NMN than rOCT1, rat kidney [102]. The expression levels of rOCT2 mRNA
and the protein in the kidney of males were much higherindicating species differences in the substrate specificity
[95]. The human genes of hOCT1 and hOCT2 (also than those in females. There was no gender difference
in mRNA expression levels of rOCT1. These findingsnamed SLC22A1 and SLC22A2) have been localized in
close proximity on chromosome 6q26 [96]. suggested that rOCT2 is responsible for the gender dif-
ferences in renal basolateral membrane organic cationSince OCT1 was cloned, other gene products with
significant homology to OCT1 have been identified (Ta- transport activity (Fig. 2, #2) [102].
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A cDNA encoding an additional member of the OCT 4.3 mmol/L, whereas it mediated some minor uptake of
TEA and guanidine [106]. The physiological functiongene family, designated as OCT3, was isolated from the
rat placenta [103]. rOCT3 is comprised of 551 amino of hOCTN2 is suggested to be a high-affinity Na1-carni-
tine cotransporter. Nezu et al [108], Tang et al [109], andacids with 12 putative transmembrane domains and
shows 48% identity to rOCT1. Northern blot analysis Wang et al [110] reported that primary systemic carnitine
deficiency, which is an autosomal recessive disease char-indicated that rOCT3 mRNA was detected most abun-
dantly in the placenta and moderately in the intestine, acterized by low serum and intracellular concentrations
of carnitine, is caused by mutations in the hOCTN2 gene.heart, and brain. Expression of rOCT3 mRNA was com-
paratively low in the kidney and lung, and it was not Interestingly, Wu et al reported that rOCTN2 is a
Na1-independent organic cation transporter as well asdetected in the liver. When expressed in HeLa cells and
Xenopus oocytes, rOCT3 induced uptake of TEA and a Na1-dependent carnitine transporter, which is ex-
pressed in the heart, kidney, placenta, and brain [111].guanidine, which could be inhibited by MPP [103]. Under
voltage-clamped conditions, rOCT3-mediated TEA up- In rat kidney, rOCTN2 mRNA is predominantly ex-
pressed in the cortex, while there is very little expressiontake evoked a potential-dependent inward current. The
current induced by the TEA uptake was markedly influ- in the medulla. In the cortical region, rOCTN2 mRNA
was found in the proximal and distal tubules. There haveenced by extracellular pH. However, such pH depen-
dence of TEA uptake by rOCT3-expressing oocytes been two mutations reported that result in amino acid
substitution in OCTN2, P478L (hOCTN2) and L352Rcould not be confirmed under voltage clamp conditions.
Therefore, rOCT3 appears to be a potential-sensitive (mouse OCTN2) [111]. These mutations in hOCTN2
cause complete loss of carnitine transport function. Inand pH gradient-independent organic cation transporter
(Fig. 2, #3). Although the distribution and localization contrast, only the M352R mutant appeared to be associ-
ated with complete loss of organic cation transport func-of rOCT3 in the kidney have not yet been determined,
it may also participate in the renal handling of a variety tion, whereas the P478L mutant had higher organic cation
of organic cations. transport activity than the wild-type transporter. These
By their homology to OCT transporters, two additional studies suggested that the binding sites for carnitine and
members of the OCT gene family, named hOCTN1 organic cations in OCTN2 exhibit significant overlap but
(SLC22A4) [104] and hOCTN2 (SLC22A5) [105, 106], are not identical. Therefore, there may be clinical implica-
have been identified (Table 1). A cDNA encoding tions for pharmacotherapy in individual patients with pri-
hOCTN1 was cloned from human fetal liver and encodes mary carnitine deficiency if the mutations in OCTN2 also
551 amino acid residue protein with 11 putative trans- affect organic cation transport activity.
membrane domains and one nucleotide binding site mo-
MDR1/P-glycoproteintif [104]. hOCTN1 mRNA was found to be abundant in
the kidney, trachea, bone marrow, fetal liver and several MDR1/P-glycoprotein, a member of the ABC multi-
human cancer cell lines, but not in adult liver. When drug transporter superfamily, mediates active extrusion
expressed in HEK293 cells, hOCTN1 mediated saturable of drugs with diverse structures, such as vinca alkaloids,
and pH-dependent uptake of TEA with higher activity anthracyclines, steroids, cyclosporines, tacrolimus, and
at neutral and alkaline than at acidic pH [107]. In addi- miscellaneous hydrophobic organic cations from the cell
tion, the efflux of TEA out of the cells was pH-depen- (Table 3) [112]. In the kidney, P-glycoprotein is ex-
dent, with an accelerated rate at acidic external medium pressed in the brush-border membranes of proximal tu-
pH. TEA uptake was not influenced by membrane po- bules, where it pumps various hydrophobic xenobiotics
tential, and hOCTN1-mediated TEA uptake was inhib- into the lumen (Fig. 2, #5) [11]. The observation that
ited by other organic cations such as cimetidine, procain- digoxin, a cardiac glycoside, appears to be actively se-
amide, quinidine, quinine, and verapamil. When expressed creted by the renal proximal tubules via P-glycoprotein
in oocytes, hOCTN1 stimulated uptake of quinidine, ver- is of particular clinical importance for transporter-medi-
apamil, and zwitterionic l-carnitine [107]. The functional ated drug interactions [113, 114].
role of OCTN1 in the renal secretion of organic cations
remains unknown.
FUNCTION AND STRUCTURE OFhOCTN2 was identified as a homologue of hOCTN1
PEPTIDE TRANSPORTERSfrom human kidney. hOCTN2 cDNA encodes a 557-
Peptide transporters expressed in the brush borderamino acid residue protein with 76% similarity to
membranes of intestinal and renal epithelial cells are in-hOCTN1 [105, 106]. hOCTN2 is strongly expressed in
volved in the efficient absorption of oligopeptides, therebythe kidney, trachea, spleen, bone marrow, skeletal mus-
contributing toward maintenance of protein nutritioncle, heart, and placenta in adult humans. When expressed
[115]. The peptide transporters mediate an electrogenicin HEK293 cells, hOCTN2 mediated the uptake of l-car-
nitine in a Na1-dependent manner with a Km value of H1-coupled cotransport of dipeptides and tripeptides,
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amino acid identity. By immunohistochemical studies,
rPEPT1 was localized to the brush-border membranes
in S1 segments of proximal tubules (Fig. 3, #1) [129] and
brush border membranes along the digestive tract [130].
In contrast, rPEPT2 protein was detected primarily in
brush border membranes of the S3 segments of proximal
tubules (Fig. 3, #2) [129]. Therefore, rPEPT1 is expressed
in early regions of the proximal tubules (pars convoluta),
whereas rPEPT2 is specific for the later regions of proxi-
mal tubules (pars recta).
We compared the recognition of b-lactam antibiotics
by LLC-PK1 cells transfected with rPEPT1 or rPEPT2
cDNA [131, 132]. Cyclacillin (aminopenicillin) and cefti-
buten (anionic cephalosporin without an a-amino group)
showed potent inhibitory effects on glycylsarcosine up-
take in the rPEPT1-expressing cells [131]. Other b-lac-
tam antibiotics, such as cephalexin, cefadroxil, and
cephradine (aminocephalosporins), showed a low inhibi-Fig. 3. Mechanisms of oligopeptide transport in renal tubular cells. Fil-
tory effect on rPEPT1-mediated glycylsarcosine uptaketered oligopeptides and several b-lactam antibiotics are reabsorbed across
brush-border membranes (BBM) by H1-coupled oligopeptide cotrans- [132]. Except for ceftibuten, these antibiotics had a much
porters, low-affinity type PEPT1 (1) and high-affinity type PEPT2 (2). more potent inhibitory effect on glycylsarcosine uptakeCellular oligopeptides, which escape hydrolytic degradation by enzymes,
via rPEPT2 than via rPEPT1. rPEPT2 was concluded toand b-lactam antibiotics are translocated across basolateral membranes
(BLM) by an unidentified peptide transporter. have a much higher affinity for b-lactam antibiotics with
an a-amino group than rPEPT1, and substituents at the
NH2-moiety of these drugs are responsible for recogni-
tion by both peptide transporters. In addition, we foundwhich is driven by an inward H1 gradient and a negative
that the a-amino group of b-lactam antibiotics interactstransmembrane potential difference [116]. Peptide trans-
with the histidine residues of rPEPT1 and rPEPT2 andporters play pharmacological roles in some medications
is involved in the mechanism of substrate recognition
as they mediate transport of peptide-like drugs such as
by these peptide transporters [133]. Site-directed point
b-lactam antibiotics [83, 117, 118], angiotensin-converting mutation analysis has suggested that both histidine resi-
enzyme (ACE) inhibitors [119] and the dipeptide-like dues at positions 57 and 121 of rPEPT1, which are con-
anticancer drug bestatin [120, 121]. Studies using isolated served in the rat, rabbit, and human PEPT1, participate
membrane vesicles have shown that the uptake of gly- in the recognition of b-lactam antibiotics by the trans-
cylsarcosine in renal brush-border membranes is medi- porter [134].
ated by at least two distinct peptide transport systems: Quinapril, an ACE inhibitor, was found to inhibit up-
the high-affinity/low-capacity and the low-affinity/high- take of glycylsarcosine by rabbit renal brush-border
capacity systems (Fig. 3) [122]. The initial uptake rate membrane vesicles [135]. The inhibition constant (Ki
of glycylsarcosine was trans-stimulated in brush-border value) of approximately 1 mmol/L was several-fold higher
membrane vesicles preloaded with cephalosporins with than the Km value for glycylsarcosine, and the interac-
an a-amino group in molecules such as cephalexin, ceph- tion appeared to be noncompetitive. On the other hand,
radine, and cyclacillin, suggesting that these antibiotics enalapril, another ACE inhibitor, was shown to inhibit
share the same peptide transporter [122]. uptake of glycylsarcosine in a competitive manner with
Molecular cloning studies have identified that two ho- a Ki value of 6 mmol/L [136]. Although the ACE inhibi-
mologous peptide transporters, designated as PEPT1 tors can interact with renal high-affinity peptide trans-
and PEPT2, are involved in mammalian epithelial trans- porter, PEPT2, it is still not known whether renal reab-
port of oligopeptides (Table 4). Fei et al identified rabbit sorption of ACE inhibitors across the brush border
PEPT1 from the intestine using expression cloning with membranes is mediated by the peptide transporters.
Xenopus oocytes [123]. Rabbit PEPT1 is comprised of Valacyclovir, a valyl ester prodrug of the antiviral
709 amino acids, with 12 putative transmembrane do- agent acyclovir, does not contain a peptide bond in its
mains. Rat [124] and human [125] homologues of rabbit structure, but it is transported by PEPT1 [137]. Vala-
PEPT1 have been isolated by hybridization techniques. cyclovir competitively inhibited glycylsarcosine uptake
Subsequently, cDNA encoding PEPT2 have been iso- in rPEPT1- or rPEPT2-expressing LLC-PK1 cells [138].
lated from rabbit [126], rat [127], and human [128] kid- rPEPT2 had higher affinity for this agent (Ki value of
0.22 mmol/L) than rPEPT1. Among several l-amino acidneys. PEPT1 and PEPT2 show approximately 50%
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Table 4. Peptide transporter family
Transporter Species Accession Chromosome Tissue distribution Substratesa
PEPT1 Human U13173 13q24-q3 Small intestine.kidney di-, tripeptides, b-lactam
Rabbit U06467 (rat) antibiotics, bestatin, ACE
Rat D50306 inhibitors, valacyclovir
PEPT2 Human S78203 3q13.3-q21 Kidney..brain, lung, di-, tripeptides, b-lactam
Rabbit U32507 spleen (rat) antibiotics, bestatin, ACE
Rat D63149 inhibitors
a The substrate specificities were examined for each rat clone
methyl esters examined, l-valine methyl ester, as well is mediated by the organic cation transporter, whereas
as valacyclovir, appeared to have high affinity for both the secretion of p-hydroxytriamterene sulfate, a metabo-
rPEPT1 and rPEPT2 [138]. From the viewpoint of drug lite of triamterene, is via the organic anion transporter.
delivery, l-valyl esterification of poorly absorbed drugs The clinical use of digoxin has been complicated by
has been postulated to be a useful strategy for improving drug interactions leading to severe drug toxicity. Using
their bioavailability and therapeutic efficacy. LLC-PK1 cells transfected with human MDR1 cDNA,
P-glycoprotein appeared to induce transepithelial trans-
port of digoxin, corresponding to tubular secretion, andCLINICAL IMPLICATIONS OF
be responsible for the digoxin–quinidine interaction [114].TRANSPORTER–MEDIATED
The interaction of digoxin and clarithromycin, a potentDRUG INTERACTIONS
macrolide antibiotic, has been observed in two patientsOrganic anion and cation transporters in the kidney
in whom plasma concentrations of digoxin were unex-are involved in the pharmacological responses to certain
pectedly elevated. In the MDR1/P-glycoprotein-express-drugs such as diuretics, and in drug–drug interactions,
ing transfectant, clarithromycin inhibited transcellularand clinically, this is of therapeutic or toxic importance
transport of digoxin and concomitantly increased cellular[139]. It is well known that probenecid inhibits renal
accumulation of digoxin [143]. These findings suggestedsecretion of other diverse anionic drugs through the or-
that clarithromycin inhibits the P-glycoprotein-mediatedganic anion transport system(s), resulting in decreased
tubular secretion of digoxin, thereby leading to an in-drug excretion. Renal excretion of ciprofloxacin, a fluoro-
crease in the plasma digoxin concentration.quinolone antibacterial drug, was decreased by coadmin-
Besides the direct interaction of drugs with drug trans-istration of probenecid in humans [140]. It has been
suggested that this type of drug interaction could be of porters described previously in this article, indirect mod-
clinical relevance for the combined use of ciprofloxacin ulation of transporter proteins could be involved in kid-
and drugs being transported by the organic anion trans- ney–specific drug interactions. In the case of organic anion
porter in the kidney. The interaction between methotrex- transporter OAT1, protein kinase C activation results in a
ate, which has been widely used for the treatment of marked decrease in its transport function [28]. Therefore,
acute leukemia, psoriasis, and rheumatoid arthritis, and agents that modulate protein kinase C activity could affect
NSAIDs has been reported with severe adverse effects the renal disposition of anionic drugs via inhibitory regula-
after chemotherapeutic use [141]. It is assumed that the tion of OAT1. For additional modification of organic
basolateral membrane OAT1 and brush-border mem- anion transporter, a selective adenosine A1 receptor antag-brane OAT-K1 and/or OAT-K2 are the organic anion
onist, KW-3902, was reported to have an inhibitory effect
transporters involved in the methotrexate–NSAIDs in-
on PAH transport in OK cells [144]. Staurosporin, a pro-teraction in the kidney [51].
tein kinase inhibitor, did not restore the KW-3902–Cimetidine and trimethoprim appeared to be potent
induced decrease in PAH transport activity, suggestinginhibitors of the renal tubular secretion of a number of
that protein kinase C may not be involved in its inhibitorycationic drugs, particularly procainamide and its active
effect. These findings are examples of indirect drug inter-metabolite N-acetylprocainamide, causing significant clin-
action based on modulation of renal drug transportersical toxicity [142]. In therapeutic doses, other histamine
rather than competitive and/or noncompetitive interac-H2 receptor antagonists may have minimal effects on
tions. In addition, compounds including drugs, xenobiot-renal procainamide elimination. Using the isolated per-
ics, and endogenous factors, which either affect or regu-fused rat kidney model, H2 antagonists such as ranitidine
late the level of expression of drug transporters, couldand famotidine were suggested to have inhibitory effects
influence renal handling of therapeutic drugs being se-on the renal secretion of triamterene [142]. These find-
ings suggested that renal tubular secretion of triamterene creted or reabsorbed in the kidney.
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